

1 **SLC25A26-mediated SAM compartmentalization coordinates translation and**
2 **bioenergetics during cardiac hypertrophy**

3 Ningning Guo^{1,2,3,4}, Jian Lv^{1,2,3,4}, Yu Fang^{1,2}, Qiuxiao Guo^{1,2}, Jiajie Li¹, Junmei Wang¹, Xiao
4 Ma², Qingqing Yan², Fuqing Jiang^{1,2}, Shuiyun Wang^{1,2}, Li Wang^{1,2,*}, Zhihua Wang^{1,2,*}

5
6 ¹Shenzhen Key Laboratory of Cardiovascular Disease, Fuwai Hospital Chinese Academy of
7 Medical Sciences, Shenzhen, Shenzhen 518057, China

8 ²State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for
9 Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical
10 College, Beijing 100037, China

11 ³Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055,
12 China

13 ⁴These authors contribute equally

14
15 *Correspondence to Zhihua Wang, PhD, Shenzhen Key Laboratory of Cardiovascular Disease,
16 Fuwai Shenzhen Hospital, Chinese Academy of Medical Sciences, Shenzhen 518057, China.
17 Email: wangzhihua@fuwaihospital.org; or Li Wang, PhD, Shenzhen Key Laboratory of
18 Cardiovascular Disease, Fuwai Shenzhen Hospital, Chinese Academy of Medical Sciences,
19 Shenzhen 518057, China. Email: wangl@pumc.edu.cn.

20
21 **Running Title:** SAM links cardiac bioenergetics to translation
22
23
24

25 **ABSTRACT**

26 **BACKGROUND:** The heart undergoes hypertrophy as a compensatory mechanism to cope with
27 increased hemodynamic stress, and it can transition into a primary driver of heart failure.
28 Pathological cardiac hypertrophy is characterized by excess protein synthesis. Protein translation
29 is an energy-intensive process that necessitates an inherent mechanism to flexibly fine-tune
30 intracellular bioenergetics according to the translation status; however, such a molecular link
31 remains lacking.

32 **METHODS:** *Slc25a26* knockout and cardiac-specific conditional knockout mouse models were
33 generated to explore its function *in vivo*. Reconstructed adeno-associated virus was used to
34 overexpress *Slc25a26* *in vivo*. Cardiac hypertrophy was established by transaortic constriction
35 (TAC) surgery. Neonatal rat ventricular myocytes were isolated and cultured to evaluate the role
36 of SLC25A26 in cardiomyocyte growth and mitochondrial biology *in vitro*. RNA sequencing
37 was conducted to explore the regulatory mechanism by SLC25A26. m¹A-modified tRNAs were
38 profiled by RNA immuno-precipitation sequencing. Label-free proteomics was performed to
39 profile the nascent peptides affected by S-adenosylmethionine (SAM).

40 **RESULTS:** We show that cardiomyocytes are among the top cell types expressing the SAM
41 transporter SLC25A26, which maintains low-level cytoplasmic SAM in the heart. SAM
42 biosynthesis is activated during cardiac hypertrophy, and feedforwardly mobilizes the
43 mitochondrial translocation of SLC25A26 to shuttle excessive SAM into mitochondria. Systemic
44 deletion of *Slc25a26* causes embryonic lethality. Cardiac-specific deletion of *Slc25a26* causes
45 spontaneous heart failure and exacerbates cardiac hypertrophy induced by transaortic
46 constriction. SLC25A26 overexpression, both before or after TAC surgery, rescues the
47 hypertrophic pathologies and protects from heart failure. Mechanistically, SLC25A26 maintains

48 low-level cytoplasmic SAM to restrict tRNA m¹A modifications, particularly at A58 and A75,
49 therefore decelerating translation initiation and modulating tRNA usage. Simultaneously,
50 SLC25A26-mediated SAM accumulation in mitochondria maintains mitochondrial fitness for
51 optimal energy production.

52 **CONCLUSIONS:** These findings reveal a previously unrecognized role of SLC25A26-mediated
53 SAM compartmentalization in synchronizing translation and bioenergetics. Targeting
54 intracellular SAM distribution would be a promising therapeutic strategy to treat cardiac
55 hypertrophy and heart failure.

56

57 **Key Words:** S-adenosylmethionine, hypertrophy, tRNA, translation, bioenergetics

58

59 **Clinical Perspective**

60 **What Is New?**

- 61 ● An activation of S-adenosylmethionine (SAM) biosynthesis during cardiac hypertrophy
62 boosts a feed-forward mitochondrial translocation of its transporter SLC25A26 to shuttle
63 excessive SAM into mitochondria.
- 64 ● SLC25A26-mediated cytoplasmic SAM containment restricts translation through inhibiting
65 TRMT61A-mediated tRNA m¹A modifications, particularly at A58 and A75, which
66 modulates translation initiation and codon usage.
- 67 ● SLC25A26-mediated mitochondrial SAM accumulation enhances mtDNA methylation and
68 is required for the implement of mitochondrial fission and mitophagy, therefore maintaining
69 optimal bioenergetics.
- 70 ● Cardiac-specific knockout of *Slc25a26* causes spontaneous heart failure, and exacerbates
71 transaortic constriction (TAC)-induced cardiac hypertrophy, while its overexpression
72 rescues the hypertrophic pathologies.

73 **What Are the Clinical Implications?**

- 74 ● Cardiomyocyte-specific expression of SLC25A26 maintains low-level cytoplasmic SAM
75 and contributes to the relatively low protein synthesis rate in the heart.
- 76 ● Targeting intracellular SAM distribution would be a promising therapeutic strategy to treat
77 cardiac hypertrophy and heart failure.

78

Nonstandard Abbreviations and Acronyms

4E-BP1	eukaryotic translation initiation factor 4E binding protein 1
5-hmdC	5-(hydroxymethyl)-2'-deoxycytidine
5-mdC	5-methyl-2'-deoxycytidine
6-mdA	N6-methyl-2'-deoxyadenosine
AAV9	adeno-associated virus serotype 9
ALKBH1/3	AlkB homolog 1/3
ATP	adenosine triphosphate
cKO	cardiac-specific conditional knockout
cytoSAM	cytoplasmic SAM
DRP1	dynamin-related protein 1
EF	ejection fraction
ELISA	Enzyme-linked immunosorbent assay
FS	fraction shortening
LC3	microtubule associated protein 1 light chain 3
LVID	left ventricular internal diameter
LVPW	left ventricular posterior wall
m1A	N1 methylated adenosine
m6A	N6 methylated adenosine
MAT2A	methionine adenosyltransferase 2A
MFF	mitochondrial fission factor
MFN2	mitofusin 2
mitoSAM	mitochondrial SAM

mTORC1	mechanistic target of rapamycin kinase complex 1
MYH6/7	myosin heavy chain 6/7
MYL4/6	myosin light chain 4/6
Nppa/Nppb	natriuretic peptide A/B
NRVMs	neonatal rat ventricular myocytes
OPA1	mitochondrial dynamin-like GTPase
RIP-seq	RNA immunoprecipitation sequencing
SAM	S-adenosylmethionine
SLC25A26/SAMC	solute carrier family 25 member 26
SQSTM1	sequestosome 1
TAC	transaortic constriction
TRMT6/61A	tRNA methyltransferase 6/61A
XIRP2	Xin actin binding repeat containing 2

80

81

82 INTRODUCTION

83 Cardiomyocytes predominantly express myofilament-related proteins, which constitute more
84 than half of the entire translome.¹ The contraction and relaxation of the myofilament require
85 substantial energy to maintain optimal cardiac performance.^{2, 3} Notably, translation also
86 consumes a significant portion of the cellular energy expenditure *per se*.⁴⁻⁶ The translation
87 activity is stringently monitored to ensure appropriate justification of the energetic investment.⁶
88 Thus, the interplay between contractility, translation and bioenergetics forms a complex triadic
89 entanglement in working cardiomyocytes. In theory, there should be an inherent mechanism that
90 coordinates these processes to provide cardiomyocytes with the necessary adaptability under
91 pathophysiological conditions; however, such a molecular link is still lacking.^{7, 8}

92 The heart undergoes hypertrophy as a compensatory mechanism to cope with increased
93 hemodynamic stress; however, if the stress persists without timely relief, hypertrophy can
94 transition into a primary driver of heart failure.⁹ Pathological cardiac hypertrophy is
95 characterized by enlarged cardiomyocyte size and excess protein synthesis.¹⁰⁻¹² Despite early
96 indications of increased ribosome biogenesis,¹³⁻¹⁵ little headway has been made in understanding
97 the regulatory mechanisms governing translational control during cardiac hypertrophy.¹⁶ While
98 gene abnormalities in cardiac hypertrophy have been extensively examined at the transcriptional
99 level, it is important to note that the cardiac translome cannot be precisely dictated by the
100 transcriptome due to ribosome efficacy and mRNA selectivity.¹⁷⁻²⁰

101 The pathological growth of cardiomyocytes is accompanied by an enhancement of
102 translation initiation.¹² Phosphorylation of eukaryotic translation initiation factor 2B ϵ by
103 glycogen synthase kinase-3 β contributes to the enhanced translation activity in β -adrenergic
104 cardiac hypertrophy.²¹ A recent study revealed that activation of inositol-requiring enzyme 1 α

105 during cardiac hypertrophy facilitates the formation of the translation initiation complex around
106 endoplasmic reticulum and promotes the translation of transcripts with 5' terminal
107 oligopyrimidine motifs.²² Translation starts with the relief of the inhibitor eukaryotic translation
108 initiation factor 4E binding protein 1 (4E-BP1) through mechanistic target of rapamycin kinase
109 complex 1 (mTORC1)-mediated phosphorylation, a process that is required for the hypertrophic
110 growth of the heart.^{23, 24} However, cardiac-specific deletion of *Raptor*, the core component of
111 mTORC1,²⁵ impairs adaptive hypertrophy, but causes heart failure in mice.²⁶ Deleting p70
112 ribosomal S6 kinase, another target of mTORC1 involving in translational activation, has no
113 effect on pressure-overload-induced cardiac hypertrophy.²⁷

114 Regulations at the tRNA level play a crucial role in fine-tuning protein synthesis in
115 response to various cellular conditions and signals.²⁸ Modifications to tRNAs affect their
116 stability, aminoacylation, and codon recognition properties, ultimately influencing the overall
117 translation process.²⁹ The initiator tRNA (tRNA^{iMet}) can be methylated at the N(1) position of
118 A58 (m¹A58) by the tRNA methyltransferase (TRMT) 6/61A complex, leading to an
119 enhancement of translation initiation.^{30, 31} Moreover, tRNA modifications can change the status
120 of the tRNA pool, leading to biased codon usage and altered translating rate of individual
121 mRNAs.³² However, it remain unclear whether tRNA modifications are involved in the
122 translational control during cardiac hypertrophy.

123 The energetic cost of protein synthesis accounts for ~30% of the total energy
124 consumption in mammalian cells.⁵ In the heart, up to 95% of adenosine triphosphate (ATP) is
125 derived from mitochondria, which occupy ~30% of the total myocardial mass.³³ Mitochondrial
126 fitness is crucial for maintaining the normal heart function; and its disorder plays a causal role in
127 heart diseases.³⁴⁻³⁶ Mitochondrial oxidative capacity has been reported to be either preserved or

128 even enhanced in cardiac hypertrophy,³⁷ but the regulatory mechanism of mitochondrial
129 dynamics under hypertrophic stress remains to be elucidated.

130 S-adenosylmethionine (SAM) is the sole methyl donor for macromolecular methylation
131 reactions.³⁸ Its biosynthesis is catalyzed by methionine adenosyltransferase 2A (MAT2A) using
132 methionine and ATP as the substrates.³⁹ The mitochondrial shuttling of SAM requires a
133 transporter named solute carrier family 25 member 26 (SLC25A26; also known as SAMC).⁴⁰ We
134 find that the cardiomyocytes express low-level MAT2A but high-level SLC25A26, making
135 mitochondria a pool of the intracellular SAM. Whereas the cytoplasmic SAM (cytoSAM)
136 enhances translation activity via tRNA m¹A modification, the mitochondrial SAM (mitoSAM)
137 maintains mitochondrial fitness through promoting fission and mitophagy. During cardiac
138 hypertrophy, an increase in SAM biosynthesis boosts the mitochondrial translocation of
139 SLC25A26 in a feedforward manner to transport excessive cytoSAM into mitochondria.
140 Cardiac-specific deletion of *Slc25a26* in mice causes spontaneous heart failure and exacerbates
141 cardiac hypertrophy induced by transaortic constriction, whereas its overexpression rescues the
142 hypertrophic pathologies. Our findings demonstrate that subcellular distribution of SAM links
143 bioenergetics with translation in cardiomyocytes, and represents a promising target for the
144 treatment of cardiac hypertrophy and heart failure.

145

146 **METHODS**

147 Collection and usage of human samples were approved by the Ethics Committee of the Fuwai
148 Hospital Chinese Academy of Medical Sciences, Shenzhen [SP2023133(01)]. Animal
149 experiments were reviewed and approved by the Institutional Animal Care and Use Committee
150 (IACUC) of Renmin Hospital of Wuhan University (No. 20180508) and the IACUC of Fuwai

151 Hospital Chinese Academy of Medical Sciences, Shenzhen (SP2023059). More details of the
152 experimental procedures are included in the Supplemental Material.

153 **Data Availability**

154 RNA-seq data have been deposited in NCBI's Gene Expression Omnibus (GEO) repository
155 (accession: GSE254565 and GSE173737). Online microarray datasets are available from NCBI's
156 GEO repository with corresponding accession codes as described in details in Supplemental
157 Methods. Any additional information reported in this paper is available from the lead contact
158 upon request.

159 **Statistical Analyses**

160 Statistical analyses were performed using GraphPad Prism 8.0 and R software. All experimental
161 data were presented as mean \pm SEM of at least three independent experiments, unless denoted
162 elsewhere. Statistical significance for multiple comparisons was determined by one-way
163 ANOVA or two-way ANOVA followed by Tukey's test. Bonferroni adjustment was used for
164 *post hoc* analysis. Student's *t* test was used for comparisons between two groups. $P < 0.05$ was
165 considered statistically significant.

166

167 **RESULTS**

168 **Feedforward Mitochondrial SAM Transport by SLC25A26 during Cardiac Hypertrophy**

169 SAM is mainly synthesized by MAT2A in cytosol,⁴¹ and can be shuttled into mitochondria by
170 SLC25A26 before donating its methyl group (Figure 1A). Human single-cell sequencing data
171 highlighted skeletal myocytes as the cell type with the highest *MAT2A* expression, versus
172 cardiomyocytes to be the lowest one (Figure 1B). On the contrary, cardiomyocytes were among

173 the top cell types expressing *SLC25A26* (Figure 1C). Western blot analysis using mouse tissues
174 validated the low expression of MAT2A in the heart, but it showed a high signal in the liver
175 (Figure 1D), possibly due to the antibody misrecognition with its hepatic-specific homolog
176 MAT1A (Figure S1A). Intriguingly, *SLC25A26* was specifically enriched in the heart (Figure
177 1D), exclusively in cardiomyocytes (Figure S1B). Enzyme-linked immunosorbent assay (ELISA)
178 showed that the level of cytoSAM was extremely low compared with mitoSAM when balanced
179 to the protein concentration; and the level of mitoSAM in the heart was roughly 3-fold higher
180 than that in the skeletal muscle and liver (Figure 1E). These results suggest a special SAM
181 distribution pattern implicated in cardiac function.

182 We then asked how the SAM biology would be shaped under cardiac stress. Both
183 MAT2A and its regulatory subunit MAT2B were significantly upregulated during the
184 development of cardiac hypertrophy after transaortic constriction (TAC) surgery in mice (Figure
185 1F), concurrent with a time-course increase in the SAM content (Figure 1G). In isolated neonatal
186 rat ventricular myocytes (NRVMs), hypertrophic stimulation by phenylephrine (PE; 50 μ M) also
187 increased the SAM content to a similar extent as exogenous SAM supplementation (1 μ M; Figure
188 1H). The PE-induced SAM increase was completely blocked by an MAT2A inhibitor AG-270
189 (3 μ M; Figure 1H),⁴² suggesting an activation of SAM biosynthesis during cardiac hypertrophy.

190 Nevertheless, the expression of *SLC25A26* showed a significant decrease after TAC
191 (Figure 1F), which was consistent with observations in human hearts with dilated
192 cardiomyopathy and mouse TAC databases (Figures S1C and S1D). Despite a decrease in
193 *SLC25A26* expression, the level of mitoSAM was still significantly elevated by TAC (Figure 1I),
194 indicating an alteration of SAM-transporting activity. To our surprise, albeit originally
195 designated as a mitochondrial protein,⁴⁰ significant amount of *SLC25A26* was detected in the
196 cytoplasmic fraction of both human and mouse hearts (Figure 1J). Yet TAC surgery caused

197 substantial translocation of SLC25A26 from cytosol to mitochondria (Figure 1K). Consistently,
198 PE treatment in NRVMs also promoted the mitochondrial translocation of SLC25A26, an effect
199 that could be mimicked by supplementing SAM but blocked by AG-270 (Figure 1L). These data
200 suggest that the increased SAM biosynthesis during cardiac hypertrophy promotes the
201 mitochondrial translocation of SLC25A26, thereby shuttling excessive cytoSAM into
202 mitochondria in a feed-forward manner.

203 **SLC25A26 Is Required for Development and Normal Heart Function**

204 To investigate the physiological function of SLC25A26, we tried to generate an *Slc25a26*-
205 knockout mouse line using CRISPR-cas9 (Figures S2A and S2B). However, homozygous
206 knockout of *Slc25a26* caused embryonic lethality (Figure S2C), suggesting an essential role of
207 SLC25A26 in development. This is consistent with previous observations that loss-of-function
208 mutations of human *SLC25A26* resulted in neonatal mortality.⁴³⁻⁴⁵

209 We then developed an inducible cardiac-specific conditional knockout (cKO) mouse line
210 by generating an *Slc25a26*-flox mouse line and hybridizing the mice with the α MHC-
211 MerCreMer transgenic mice (Figure 2A), so that enabling controllable *Slc25a26* deletion in adult
212 cardiomyocytes (Figure 2B).⁴⁶ *Slc25a26* cKO did not influence the heart weight but significantly
213 increased the lung weight twenty weeks after tamoxifen administration (Figures 2C and 2D), a
214 characteristic symptom of heart failure. Echocardiography showed that *Slc25a26* deficiency led
215 to enlarged left ventricular internal diameter (LVID) both in diastole and in systole and impaired
216 the ejection fraction (EF) and fraction shortening (FS) (Figures 2E through 2G). Moreover, the
217 *Slc25a26*-cKO hearts exhibited severe myocardial fibrosis (Figure 2H) and robust inductions of
218 pathological markers, including natriuretic peptide A (*Nppa*), natriuretic peptide B (*Nppb*), and
219 myosin heavy chain 7 (*Myh7*), compared with the *Slc25a26*-flox hearts (Figure 2I). These data

220 suggest an essential role of SLC25A26 in the maintenance of normal heart morphology and
221 function.

222 **SLC25A26 Suppresses Cardiac Hypertrophy**

223 To evaluate the impact of SLC25A26 on pathological cardiac hypertrophy, we subjected the
224 *Slc25a26*-cKO mice (5w after tamoxifen administration) to TAC surgery. Loss of *Slc25a26*
225 significantly elevated the TAC-induced heart weight gain (Figure 2J), and caused severe
226 pulmonary edema in the TAC group (Figure 2K). Echocardiography detected an increased left
227 ventricular posterior wall (LVPW) thickness after TAC, without any change in LVID, in the
228 *Slc25a26*-cKO hearts compared with the *Slc25a26*-flox hearts (Figures 2L and 2M). Moreover,
229 deletion of *Slc25a26* exacerbated the TAC-induced contractility impairment and accelerated the
230 development of heart failure (Figure 2N). At the histological level, *Slc25a26* cKO aggravated the
231 TAC-induced cardiomyocyte enlargement (Figures 2O and 2P) and myocardial fibrosis (Figure
232 2Q). At the molecular level, the post-TAC inductions of *Nppa*, *Nppb*, and *Myh7* were further
233 potentiated by *Slc25a26* deficiency (Figure 2R). Consistently, *Slc25a26* haploinsufficiency also
234 exhibited worsened hypertrophic pathologies after TAC (Figures S2D through S2J). These data
235 highlight a protective role of SLC25A26 against cardiac hypertrophy.

236 To examine the inhibitory effect of SLC25A26 on cardiac hypertrophy, we reconstructed
237 adeno-associated virus (AAV9) to overexpress *Slc25a26* in the heart two weeks before TAC
238 surgery (Figures 3A and 3B). *Slc25a26* overexpression significantly restricted the TAC-induced
239 heart weight gain compared with the AAV9-*Vector* control group (Figure 3C). Echocardiography
240 showed that the post-TAC enlargements of LVPW thickness and LVID were significantly
241 blunted by *Slc25a26* overexpression (Figures 3D and 3E); and the post-TAC declines of EF and
242 FS were significantly rescued by *Slc25a26* overexpression (Figure 3F). Moreover, *Slc25a26*

243 overexpression significantly attenuated the cardiomyocyte enlargement (Figure 3G), myocardial
244 fibrosis (Figure 3H), and the induction of pathological genes after TAC (Figure 3I).

245 We then challenged whether SLC25A26 would be sufficient to deliver therapeutic
246 benefits by overexpressing *Slc25a26* after TAC in two injection schedules: 1w post-TAC and 7w
247 post-TAC (Figures 3J and 3K). In both strategies, *Slc25a26* overexpression significantly
248 suppressed the TAC-induced heart weight gain (Figure 3L) and restored the declines of EF and
249 FS (Figures 3M and 3N). Notably, *Slc25a26* overexpression at 7w post-TAC significantly
250 rescued the functional decline of the failing hearts (Figure 3O). Moreover, the TAC-induced
251 cardiomyocyte enlargement (Figure 3P), myocardial fibrosis (Figure 3Q), and the induction of
252 pathological markers (Figures 3R and 3S) were all substantially reversed by post-TAC *Slc25a26*
253 overexpression. These data suggest a promising SLC25A26-based gene therapy to treat cardiac
254 hypertrophy.

255 In line with the *in vivo* findings, the PE-induced hypertrophy of NRVMs was
256 significantly exacerbated by silencing *Slc25a26*, but alleviated by its overexpression (Figures
257 S3A through S3F).

258 **SLC25A26 Negatively Regulates Translation Activity**

259 To explore the underlying mechanisms, we performed a transcriptome analysis. Principal
260 component analysis showed that *Slc25a26* deficiency caused a generally pro-hypertrophic
261 transcriptome reprogramming (Figure 4A). Gene-concept network analysis highlighted the
262 pathways of aminoacyl-tRNA ligase activity and tRNA aminoacylation for protein translation
263 among the top enriched functional terms affected by *Slc25a26* deletion (Figure 4B). In detail,
264 nearly all cytosol aminoacyl-tRNA synthetases, but not their mitochondrial counterparts, were
265 substantially upregulated in the *Slc25a26*-cKO hearts compared with the *Slc25a26*-flox controls

266 (Figure 4C). Concurrently, gene set enrichment analysis revealed a remarkable upregulation of
267 ribosome-biogenesis-associated genes (Figure 4D), suggesting a crucial role of SLC25A26 in
268 translational regulation.

269 We then performed an *in vivo* puromycin incorporation assay to directly assess
270 translation activity. The heart presented the lowest protein synthesis rate among the organs tested
271 (Figure S4A). The protein synthesis rate was significantly accelerated in the *Slc25a26*-cKO
272 hearts but suppressed in the hearts with *Slc25a26* overexpression, compared with corresponding
273 controls (Figures 4E and 4F). Consistently, silencing *Slc25a26* in NRVMs significantly
274 accelerated the protein synthesis rate and further enhanced its activation by PE (Figure S4B),
275 while *Slc25a26* overexpression exhibited opposite effects (Figure S4C). However, *Slc25a26*
276 knockdown failed to re-activate translation when the SAM biosynthesis was inhibited by AG-
277 270, which displayed robust suppression on basal translation activity (Figures S4D and S4E). On
278 the other hand, SAM supplementation largely rescued the inhibitory effect of *Slc25a26*
279 overexpression on translation (Figure S4F). These data suggest that the translation-repressing
280 role of SLC25A26 relies on its function as a SAM transporter.

281 **SLC25A26 Modulates tRNA m¹A Profiles and Translation Initiation**

282 Since SAM-dependent tRNA methylation is critical for its maturation and the decoding process
283 during translation,^{47, 48} we hypothesized that SLC25A26-mediated cytoSAM containment might
284 regulate translation through modulating tRNA methylation. In the *Slc25a26*-cKO hearts, an
285 increase in cytoSAM did not affect the N(6)-methyladenosine (m⁶A) level of total RNAs, but
286 significantly enhanced the level of m¹A (Figure 4G), a modification that mainly occurs on
287 tRNAs.⁴⁷⁻⁴⁹ Then we performed RNA immunoprecipitation sequencing (RIP-seq) using an m¹A-
288 specific antibody to profile the tRNA m¹A landscape at single-nucleotide resolution. Out of the

289 400 predicted mouse tRNA isotypes, we identified 202 tRNAs with detectable m¹A modification
290 (Table S1), among which 37 tRNAs were found to be enhanced in m¹A modification in the
291 *Slc25a26*-cKO hearts compared with the *Slc25a26*-flox controls, versus only 16 tRNAs were
292 downregulated (Figure 4H). Interestingly, *Slc25a26* deficiency specifically enhanced the m¹A
293 modification on tRNA^{iMet}, but not on its methionine elongation counterpart (tRNA^{Met}; Figure
294 4H), suggesting that the methylation sensitivity of tRNA^{iMet} to SLC25A26-mediated cytoSAM
295 containment governs translation initiation. Indeed, silencing *Slc25a26* in NRVMs significantly
296 enhanced translation initiation efficiency from both 5'-cap and internal ribosome entry sites
297 (IRES) in a luciferase reporter system (Figure 4I).

298 **SAM-sensitive tRNA m¹A Patterns Remodel Cardiac Translatome**

299 Status of the tRNA pool determines codon usage that influences the translating rate of
300 individual mRNAs.^{32, 50} We found that the m¹A modifications after *Slc25a26* deletion were
301 diversified among different tRNA categories (Figure 4J), as well as among different tRNA
302 isotypes for certain amino acids (Figures 4K and 4L). For instance, the m¹A levels were largely
303 elevated in corresponding tRNAs of Asn, Asp, Cys, Ser, Val and Sec (selenocysteine), but were
304 reduced in those for Ala, His, Trp and Sup (stop codon) after *Slc25a26* knockout (Figure 4J).

305 To characterize the impact of the cytoSAM-sensitive tRNA m¹A modifications on
306 translation dynamics, we performed a label-free proteomics analysis for the enriched puromycin-
307 incorporated nascent peptides from NRVMs with different *Slc25a26* manipulations (Figure 4M).
308 We identified 4262 peptides corresponding to 713 proteins, among which 203 proteins were
309 altered by *Slc25a26* knockdown and 92 proteins were altered by its overexpression (Figure 4N).
310 Surprisingly, heart-specific proteins, such as myosin heavy chain (MYH) 6/7, myosin light chain
311 (MYL) 4/6, and Xin actin binding repeat containing (XIRP) 2, were enriched in the

312 downregulated proteins after *Slc25a26* knockdown (Figure 4O). Whereas proteins related to
313 ribosome and cardiac muscle contraction were suppressed by *Slc25a26* knockdown, proteasome-
314 related proteins were highly enriched in the upregulated proteins (Figure 4P). *Slc25a26*
315 overexpression generally showed an opposite regulation of these pathways (Figure 4Q). These
316 data suggest a compensatory response to reduce ribosome biogenesis and to augment protein
317 degradation upon *Slc25a26* deficiency. When mapped to the transcriptional changes, roughly
318 61% proteins, such as XIRP1, MYL4, MYL6, guanylate binding protein 1, signal transducer and
319 activator of transcription 1, tripartite motif containing 21, and collagen type I alpha 1, showed
320 consistent alterations with their mRNA levels; whereas 39% proteins, such as XIRP2,
321 sequestosome 1 (SQSTM1), receptor for activated C kinase 1, and junction plakoglobin, could
322 not be interpreted by their transcriptional alterations (Figure 4R). These data suggest that
323 SLC25A26-mediated biased codon usage remodels cardiac translome.

324 **tRNA m¹A Modification Contributes to SLC25A26-mediated Translational Control**

325 When aligning all the m¹A sites together, we found that the SAM-sensitive m¹A
326 modification mainly occurred within the T-arm and the acceptor region of tRNAs, particularly at
327 A58 and A75 (the last nucleotide for esterification with cognate amino acids) (Figure 5A).
328 Typical m¹A-modified sites were illustrated in tRNA^{iMet}, tRNA^{Gln}, and tRNA^{Thr} (Figure 5B).
329 However, two tRNA categories, tRNA^{Glu} and tRNA^{Gly}, exhibited distinct m¹A modification
330 patterns specifically in the D arm (Figure 5C). The m¹A75 modification has not been reported
331 before, but the m¹A58 modification is well-known for its critical role in tRNA maturation and
332 coding.⁴⁷⁻⁴⁹ TRMT6 and TRMT61A function as the methyltransferases for A58 of tRNAs;⁵¹⁻⁵³
333 however, only TRMT61A could be verified necessary for maintaining the normal translation
334 activity in NRVMs (Figures 5D and 5E). Silencing *Trmt61a* significantly reversed the
335 acceleration of the protein synthesis rate by *Slc25a26* knockdown (Figure 5F). Moreover,

336 AAV9-shRNA-mediated *in vivo* knockdown of *Trmt61a* significantly blunted the accelerated
337 protein synthesis rate in the *Slc25a26*-cKO hearts (Figures S5A and S5B), albeit that it did not
338 rescue the TAC-induced heart failure (Figures S5C and S5D). On the other hand, m¹A58 can be
339 demethylated by *AlkB* homolog 1 (ALKBH1) and ALKBH3.⁵⁴⁻⁵⁶ Whereas silencing each gene
340 could both enhance translation activity (Figures 5G and 5H), silencing *Alkbh3* displayed more
341 robust recovery of the restricted translation after *Slc25a26* overexpression than silencing *Alkbh1*
342 (Figures 5I and 5J). These data suggest that tRNA m¹A modification mediates the translational
343 regulation by SLC25A26.

344 **mitoSAM Maintains Mitochondrial Fitness for Optimal Energy Production**

345 SAM-dependent methylation reactions are crucial for the normal function of mitochondria,⁵⁷ so
346 we became curious about the impact of SLC25A26 on mitochondrial biology. The mitoSAM
347 level in the heart was reduced by *Slc25a26* cKO but increased by its overexpression (Figure 6A).
348 Nuclear DNA represents a primary methylation substrate sensitive to SAM abundance;⁴³
349 however, it remains under debate whether the mitochondrial DNA (mtDNA) can be
350 methylated.⁵⁸ To address this question, we performed mass spectrometry with purified mtDNA,
351 and found that SLC25A26-mediated mitoSAM accumulation significantly increased the level of
352 5-methyl-2'-deoxycytidine (5-mdC) with marginal effects on 5-(hydroxymethyl)-2'-
353 deoxycytidine (5-hmdC) or N6-methyl-2'-deoxyadenosine (6-mdA) in mtDNA (Figure 6B).
354 ELISA analysis also confirmed that the 5-mdC amount of mtDNA was reduced in the *Slc25a26*-
355 cKO hearts but augmented in the hearts with *Slc25a26* overexpression, compared with
356 corresponding controls (Figure 6C). Moreover, *Slc25a26* overexpression in NRVMs increased
357 the 5-mdC level in mtDNA but reduced that in the nuclear DNA (Figure S6A). Nevertheless,
358 *Slc25a26* manipulations did not influence the mitochondria copy number (Figures 6D and S6B).

359 Transmission electron microscope showed that *Slc25a26* deficiency significantly
360 impaired the mitochondrial morphology in the heart (Figure 6E), whereas *Slc25a26*
361 overexpression significantly ameliorated the severity of mitochondrial damage after TAC (Figure
362 6F). To explore the underlying mechanism, we screened the expression of proteins related to
363 mitochondrial dynamics. Whereas the fusion-related proteins mitofusin 2 (MFN2) and
364 mitochondrial dynamin-like GTPase (OPA1) did not change after *Slc25a26* deletion, the fission-
365 related proteins dynamin-related protein 1 (DRP1) and mitochondrial fission factor (MFF) were
366 significantly down-regulated (Figure 6G). Moreover, *Slc25a26* deficiency caused significant
367 accumulation of mitophagy-related proteins Parkin and SQSTM1 (also known as p62), but
368 inhibited microtubule associated protein 1 light chain 3 (LC3) lipidation (Figure 6G), suggesting
369 a stagnancy of mitophagy. Similar alteration patterns were observed in NRVMs with *Slc25a26*
370 knockdown (Figure S6C). Furthermore, inhibiting SAM biosynthesis by AG-270 caused a
371 significant decrease of MFF and accumulation of SQSTM1 in despite of a complete depletion of
372 Parkin (Figure S6D). Fluorescent imaging with mito-Keima, a mitophagy indicator,⁵⁹ showed
373 that *Slc25a26* knockdown in NRVMs significantly reduced the engulfment of mitochondria by
374 lysosome (Figure 6H), and this process was oppositely promoted by *Slc25a26* overexpression
375 (Figure 6I). These data suggest that the mitochondrial uptake of SAM is required for the
376 implementation of mitochondrial fission and mitophagy, which are sequentially dependent
377 processes for mitochondrial quality control.⁶⁰

378 To validate the functional outcome, we performed the JC-1 staining to measure the
379 mitochondrial membrane potential. PE-induced decline in mitochondrial membrane potential
380 was significantly exacerbated by *Slc25a26* knockdown (Figure 6J), but reversed by its
381 overexpression (Figure 6K). Consistently, mitochondrial bioenergetics assay (Seahorse) showed
382 that *Slc25a26* knockdown substantially impaired the mitochondrial respiratory capacity (Figure

383 6L), whereas its overexpression caused an improvement in oxygen consumption rate and ATP
384 production in an AG-270-sensitive manner (Figure 6M). These results suggest that SLC25A26-
385 mediated mitochondrial fitness benefits cardiac bioenergetics, thereby synchronizing the energy
386 production efficacy with the translation status.

387

388 **DISCUSSION**

389 Coordination between translation and bioenergetics is prerequisite for cell flexibility in varying
390 environments; however, such a molecular link is still missing.^{4-6, 8} Our study demonstrates an
391 essential role of SLC25A26-mediated SAM compartmentalization in coordinating translational
392 control and mitochondrial quality control in cardiomyocytes, thus providing the first proof to
393 address this long-standing question.

394 As the principal methyl donor, the fundamental role of SAM in life activities is self-
395 evident. Firstly, the methyl group is the simplest organic structural unit. Secondly, SAM is
396 derived from methionine, the start amino acid for translation initiation. Thirdly, SAM
397 metabolism pathways are highly conserved among organisms.⁶¹ Nonetheless, our current
398 understanding about the regulation of SAM biology under pathophysiological conditions remains
399 limited. Here we reveal an increased SAM biosynthesis during the development of cardiac
400 hypertrophy, which drives the mitochondrial translocation of SLC25A26 to shuttle excessive
401 cytoSAM into mitochondria. This regulatory circuit manifests a rare feedforward mechanism that
402 provides a reasonable explanation for the relatively low-level cytoSAM compared to mitoSAM
403 in the heart. It is astonishing that endogenous SLC25A26 is not strictly a mitochondrial protein
404 as originally proposed in Chinese hamster ovary (CHO) cells⁴⁰. In cardiomyocytes, the
405 mitochondrial location of SLC25A26 is adjustable depending on the cellular SAM abundance

406 (Figures 1K and 1L). This is supported by a previous report by Wang et al.⁶² that SLC25A26 was
407 partially co-localized with mitochondria and could form hexamer, a possible existence form in
408 cytosol, as analyzed by size-exclusion chromatography.

409 The fact that the expression of SLC25A26 is mostly enriched in the heart indicates a
410 special need of the cardiomyocyte to balance the levels of cytoSAM and mitoSAM. In fact, the
411 protein synthesis rate in the heart is among the slowest compared with other tissues (Figure
412 S4A). This concept is further supported by previous observations that the turnover of cardiac
413 sarcomere proteins was relatively slow to maintain normal contractile function^{10, 20, 63}. Our data
414 showed that the protein synthesis rate was highly sensitive to the expression alteration of
415 SLC25A26 (Figures 4E, 4F, and S4B-S4F), suggesting that the strict translational control in
416 cardiomyocytes might be attributable to the low-level cytoSAM maintained by SLC25A26.

417 Our findings verify tRNA m¹A modification to be the key mechanism underpinning the
418 translational control by SLC25A26 and cytoSAM. The m¹A58 modification is a conserved
419 feature of all tRNA variants, and has been thought to aid tRNA maturation, stability and
420 decoding.⁴⁷⁻⁴⁹ Evidence in this study implicates that m¹A58 is not strictly required for the
421 housekeeping function of the tRNA but can be regulated by SAM availability, and serves as a
422 gearbox to finetune the translation efficiency. The m¹A58 modification on tRNA^{iMet} has been
423 reported to promote translation initiation, but its pathophysiological relevance in human diseases
424 has been lacking until very recently.⁵⁴ The alteration in m¹A58 level provides a mechanistic
425 explanation for how proteins are excessively synthesized during cardiac hypertrophy as a result
426 of enhanced SAM biosynthesis. Our data also validated the bidirectional regulation of m¹A58 by
427 the writer TRMT61A and the erasers ALKBH1/3.⁵²⁻⁵⁴ These modulators provide a
428 comprehensive tool box to modify the translation status by manipulating the level of m¹A58.
429 Moreover, we identified m¹A75 for the first time as a novel methylation event that was

430 remarkably abundant in tRNAs (Figure 5A). Considering that this is the last nucleotide for
431 esterification with cognate amino acids, m¹A75 might have crucial functions in translational
432 regulation.

433 Beyond translation initiation, we also provide proof-of-concept evidence for the biased
434 codon usage derived from diversified tRNA m¹A modifications in mammalian cells. The uneven
435 use of synonymous codons in the transcriptome serves as a secondary genetic code guiding
436 translation efficiency and fidelity.⁶⁴ Synonymous codon usage can have a substantial influence
437 on protein synthesis rates.⁶⁵ Highly expressed genes exhibit improved adaptation of the codons to
438 the tRNA pool.⁶⁶ Li et al.⁶⁷ found that tRNA m⁵C modification stabilizes tRNA^{Leu}, contributing
439 to a codon-dependent translation bias to support a pro-cancer translation program. Our data
440 reveal that m¹A modifications to different tRNA variants and different isoforms of certain tRNA
441 category possess diversified sensitivity to the SAM availability. This mechanism is preferentially
442 leveraged by the cardiomyocytes to tailor the proteome under hypertrophic stress. Nevertheless,
443 how these changes participate in pathogenesis of cardiac hypertrophy requires further validation
444 in details.

445 Mitochondrial fission enables clearance of dysfunctional mitochondria through
446 mitophagy to maintain the integrity of the energy system.⁶⁰ The high enrichment of SAM makes
447 mitochondria a pool for intracellular SAM, a unique pattern usually adopted by ions (e.g.
448 calcium) rather than metabolites. SLC25A26-mediated increase in mitoSAM is accompanied by
449 enhanced mitochondrial fission, mitophagy and ATP production, suggesting an important role of
450 SLC25A26/mitoSAM in mitochondrial quality control. Although we did not clarify the direct
451 effectors, the regulation of mitochondrial biology by mitoSAM is closely related to its impact on
452 mtDNA methylation. Certain isoforms of DNA methyltransferases can enter mitochondria to
453 catalyze mtDNA methylation, which has been associated with mitochondrial replication,

454 dynamics and bioenergetics.^{68, 69} *Slc25a26* mutations in human cause intra-mitochondrial
455 methylation deficiency, and are associated with neonatal mortality resulting from respiratory
456 insufficiency and hydrops, childhood acute episodes of cardiopulmonary failure, and slowly
457 progressive muscle weakness,⁴³⁻⁴⁵ suggesting an essential role of SLC25A26-mediated
458 mitochondrial homeostasis during development.

459 Putting the differential functions of cytoSAM and mitoSAM in the context of cardiac
460 hypertrophy, a rational deduction is that the enhanced SAM biosynthesis and transport are
461 intrinsic protective mechanisms to compensate for the increased contractility and energy
462 demands of cardiomyocytes under pressure overload. However, excessive protein synthesis
463 under long-term stress might exhaust the mitochondria for faster and faster ATP generation,
464 eventually leading to decompensation and the transition from cardiac hypertrophy to heart
465 failure.⁷⁰ In this case, SLC25A26 overexpression is efficient to lower cytoSAM but increase
466 mitoSAM, resulting in translation slowdown and mitochondrial fitness. This scenario provides a
467 promising gene-therapy strategy to kill two birds with one stone.

468 Taken together, our study demonstrates SLC25A26-mediated SAM compartmentalization
469 as a molecular link between translation control and mitochondrial quality control. Targeting
470 intracellular SAM distribution would be a promising therapeutic strategy to treat cardiac
471 hypertrophy and heart failure.

472

473 **ARTICLE INFORMATION**

474 **Affiliations**

475 Shenzhen Key Laboratory of Cardiovascular Disease, Fuwai Shenzhen Hospital Chinese
476 Academy of Medical Sciences (NG, JLv, YF, QG, JLi, JW, FJ, SW, LW, ZW), State Key

477 Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular
478 Disease, Chinese Academy of Medical Sciences and Peking Union Medical College (NG, JLv,
479 YF, FJ, SW, LW, ZW), Shenzhen Institute of Advanced Technology, Chinese Academy of
480 Sciences (NG, JLv).

481 **Acknowledgments**

482 We would like to thank Yingying Guo and Shun Wang from Wuhan University for their
483 assistance on animal experiments. Mito-Keima plasmid was a gift from Dr. Moshi Song's lab.

484 **Sources of Funding**

485 This work was supported by grants from National Key R&D Program of China
486 (2022YFA1104500 to LW and ZW), National Natural Science Foundation of China (82370392,
487 82070231 and 81722007 to ZW), CAMS Innovation Fund for Medical Sciences (2023-I2M-1-
488 003 and 2022-I2M-2-001 to LW and ZW), Non-profit Central Research Institute Fund of
489 Chinese Academy of Medical Sciences (2019PT320026 to LW and ZW), National High Level
490 Hospital Clinical Research Funding (2022-GSP-GG-7 to LW and ZW), Shenzhen Medical
491 Research Fund (B2302026 to ZW), Shenzhen Fundamental Research Program
492 (ZDSYS20200923172000001 to ZW), and Science, Technology and Innovation Commission of
493 Shenzhen Municipality (RCJC20210706091947009 to ZW; RCBS20221008093333076 to NG).

494 **Disclosures**

495 None.

496 **Supplemental Material**

497 Supplemental Methods

498 Figures S1-S6

499 Tables S1-S2

500 Supplemental References

501

502 **REFERENCES**

- 503 1. Yin X, Cuello F, Mayr U, Hao Z, Hornshaw M, Ehler E, Avkiran M and Mayr M.
504 Proteomics analysis of the cardiac myofilament subproteome reveals dynamic alterations in
505 phosphatase subunit distribution. *Mol Cell Proteomics*. 2010;9:497-509.
- 506 2. Ventura-Clapier R, Garnier A, Veksler V and Joubert F. Bioenergetics of the failing heart.
507 *Biochim Biophys Acta*. 2011;1813:1360-72.
- 508 3. Muangkram Y, Noma A and Amano A. A new myofilament contraction model with ATP
509 consumption for ventricular cell model. *J Physiol Sci*. 2018;68:541-554.
- 510 4. Buttgereit F and Brand MD. A hierarchy of ATP-consuming processes in mammalian
511 cells. *Biochem J*. 1995;312 (Pt 1):163-7.
- 512 5. Li GW, Burkhardt D, Gross C and Weissman JS. Quantifying absolute protein synthesis
513 rates reveals principles underlying allocation of cellular resources. *Cell*. 2014;157:624-35.
- 514 6. Marchingo JM and Cantrell DA. Protein synthesis, degradation, and energy metabolism
515 in T cell immunity. *Cell Mol Immunol*. 2022;19:303-315.
- 516 7. Kamoun D, Behar J, Leichner JM and Yaniv Y. Bioenergetic Feedback between Heart
517 Cell Contractile Machinery and Mitochondrial 3D Deformations. *Biophys J*. 2018;115:1603-
518 1613.
- 519 8. Yang X, Heinemann M, Howard J, Huber G, Iyer-Biswas S, Le Treut G, Lynch M,
520 Montooth KL, Needleman DJ, Pigolotti S, Rodenfels J, Ronceray P, Shankar S, Tavassoly I,
521 Thutupalli S, Titov DV, Wang J and Foster PJ. Physical bioenergetics: Energy fluxes, budgets,

- 522 and constraints in cells. *Proc Natl Acad Sci U S A*. 2021;118.
- 523 9. Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, Rowin EJ,
524 Maron MS and Sherrid MV. Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC
525 State-of-the-Art Review. *J Am Coll Cardiol*. 2022;79:372-389.
- 526 10. Lam MP, Wang D, Lau E, Liem DA, Kim AK, Ng DC, Liang X, Bleakley BJ, Liu C,
527 Tabaraki JD, Cadeiras M, Wang Y, Deng MC and Ping P. Protein kinetic signatures of the
528 remodeling heart following isoproterenol stimulation. *J Clin Invest*. 2014;124:1734-44.
- 529 11. Maillet M, van Berlo JH and Molckentin JD. Molecular basis of physiological heart
530 growth: fundamental concepts and new players. *Nat Rev Mol Cell Biol*. 2013;14:38-48.
- 531 12. Nakamura M and Sadoshima J. Mechanisms of physiological and pathological cardiac
532 hypertrophy. *Nat Rev Cardiol*. 2018;15:387-407.
- 533 13. Morgan HE, Siehl D, Chua BH and Lautensack-Belser N. Faster protein and ribosome
534 synthesis in hypertrophying heart. *Basic Res Cardiol*. 1985;80 Suppl 2:115-8.
- 535 14. Rosello-Lleti E, Rivera M, Cortes R, Azorin I, Sirera R, Martinez-Dolz L, Hove L, Cinca
536 J, Lago F, Gonzalez-Juanatey JR, Salvador A and Portoles M. Influence of heart failure on
537 nucleolar organization and protein expression in human hearts. *Biochem Biophys Res Commun*.
538 2012;418:222-8.
- 539 15. Guo N, Zheng D, Sun J, Lv J, Wang S, Fang Y, Zhao Z, Zeng S, Guo Q, Tong J and Wang
540 Z. NAP1L5 Promotes Nucleolar Hypertrophy and Is Required for Translation Activation During
541 Cardiomyocyte Hypertrophy. *Front Cardiovasc Med*. 2021;8:791501.
- 542 16. Hannan RD, Jenkins A, Jenkins AK and Brandenburger Y. Cardiac hypertrophy: a matter
543 of translation. *Clin Exp Pharmacol Physiol*. 2003;30:517-27.
- 544 17. Witte F, Ruiz-Orera J, Mattioli CC, Blachut S, Adami E, Schulz JF, Schneider-Lunitz V,
545 Hummel O, Patone G, Mucke MB, Silhavy J, Heinig M, Bottolo L, Sanchis D, Vingron M,

546 Chekulaeva M, Pravenec M, Hubner N and van Heesch S. A trans locus causes a ribosomopathy
547 in hypertrophic hearts that affects mRNA translation in a protein length-dependent fashion.
548 *Genome Biol.* 2021;22:191.

549 18. van Heesch S, Witte F, Schneider-Lunitz V, Schulz JF, Adami E, Faber AB, Kirchner M,
550 Maatz H, Blachut S, Sandmann CL, Kanda M, Worth CL, Schafer S, Calviello L, Merriott R,
551 Patone G, Hummel O, Wyler E, Obermayer B, Mucke MB, Lindberg EL, Trnka F, Memczak S,
552 Schilling M, Felkin LE, Barton PJR, Quaife NM, Vanezis K, Diecke S, Mukai M, Mah N, Oh SJ,
553 Kurtz A, Schramm C, Schwinge D, Sebode M, Harakalova M, Asselbergs FW, Vink A, de Weger
554 RA, Viswanathan S, Widjaja AA, Gartner-Rommel A, Milting H, Dos Remedios C, Knosalla C,
555 Mertins P, Landthaler M, Vingron M, Linke WA, Seidman JG, Seidman CE, Rajewsky N, Ohler
556 U, Cook SA and Hubner N. The Translational Landscape of the Human Heart. *Cell.*
557 2019;178:242-260 e29.

558 19. Doroudgar S, Hofmann C, Boileau E, Malone B, Riechert E, Gorska AA, Jakobi T,
559 Sandmann C, Jurgensen L, Kmietczyk V, Malovrh E, Burghaus J, Rettel M, Stein F, Younesi F,
560 Friedrich UA, Mauz V, Backs J, Kramer G, Katus HA, Dieterich C and Volkers M. Monitoring
561 Cell-Type-Specific Gene Expression Using Ribosome Profiling In Vivo During Cardiac
562 Hemodynamic Stress. *Circ Res.* 2019;125:431-448.

563 20. Lau E, Cao Q, Lam MPY, Wang J, Ng DCM, Bleakley BJ, Lee JM, Liem DA, Wang D,
564 Hermjakob H and Ping P. Integrated omics dissection of proteome dynamics during cardiac
565 remodeling. *Nat Commun.* 2018;9:120.

566 21. Hardt SE, Tomita H, Katus HA and Sadoshima J. Phosphorylation of eukaryotic
567 translation initiation factor 2Bepsilon by glycogen synthase kinase-3beta regulates beta-
568 adrenergic cardiac myocyte hypertrophy. *Circ Res.* 2004;94:926-35.

569 22. Li C, Li S, Zhang G, Li Q, Song W, Wang X, Cook JA, van der Stoel M, Wright BW,

- 570 Altamirano F, Niewold EL, Han J, Kimble G, Zhang P, Luo X, Urra H, May HI, Ferdous A, Sun
571 XN, Deng Y, Ikonen E, Hetz C, Kaufman RJ, Zhang K, Gillette TG, Scherer PE, Hill JA, Chen J
572 and Wang ZV. IRE1alpha Mediates the Hypertrophic Growth of Cardiomyocytes Through
573 Facilitating the Formation of Initiation Complex to Promote the Translation of TOP-Motif
574 Transcripts. *Circulation*. 2024.
- 575 23. Gingras AC, Gygi SP, Raught B, Polakiewicz RD, Abraham RT, Hoekstra MF, Aebersold
576 R and Sonenberg N. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. *Genes
577 Dev*. 1999;13:1422-37.
- 578 24. Zhang D, Contu R, Latronico MV, Zhang J, Rizzi R, Catalucci D, Miyamoto S, Huang K,
579 Ceci M, Gu Y, Dalton ND, Peterson KL, Guan KL, Brown JH, Chen J, Sonenberg N and
580 Condorelli G. mTORC1 regulates cardiac function and myocyte survival through 4E-BP1
581 inhibition in mice. *J Clin Invest*. 2010;120:2805-16.
- 582 25. Schalm SS, Fingar DC, Sabatini DM and Blenis J. TOS motif-mediated raptor binding
583 regulates 4E-BP1 multisite phosphorylation and function. *Curr Biol*. 2003;13:797-806.
- 584 26. Shende P, Plaisance I, Morandi C, Pellieux C, Berthonneche C, Zorzato F, Krishnan J,
585 Lerch R, Hall MN, Ruegg MA, Pedrazzini T and Brink M. Cardiac raptor ablation impairs
586 adaptive hypertrophy, alters metabolic gene expression, and causes heart failure in mice.
587 *Circulation*. 2011;123:1073-82.
- 588 27. McMullen JR, Shioi T, Zhang L, Tarnavski O, Sherwood MC, Dorfman AL, Longnus S,
589 Pende M, Martin KA, Blenis J, Thomas G and Izumo S. Deletion of ribosomal S6 kinases does
590 not attenuate pathological, physiological, or insulin-like growth factor 1 receptor-
591 phosphoinositide 3-kinase-induced cardiac hypertrophy. *Mol Cell Biol*. 2004;24:6231-40.
- 592 28. Orellana EA, Siegal E and Gregory RI. tRNA dysregulation and disease. *Nat Rev Genet*.
593 2022;23:651-664.


- 594 29. Gu C, Begley TJ and Dedon PC. tRNA modifications regulate translation during cellular
595 stress. *FEBS Lett.* 2014;588:4287-96.
- 596 30. Macari F, El-Houfi Y, Boldina G, Xu H, Khoury-Hanna S, Ollier J, Yazdani L, Zheng G,
597 Bieche I, Legrand N, Paulet D, Durrieu S, Bystrom A, Delbecq S, Lapeyre B, Bauchet L,
598 Pannequin J, Hollande F, Pan T, Teichmann M, Vagner S, David A, Choquet A and Joubert D.
599 TRM6/61 connects PKC α with translational control through tRNAⁱ(Met) stabilization:
600 impact on tumorigenesis. *Oncogene.* 2016;35:1785-96.
- 601 31. Anderson J, Phan L, Cuesta R, Carlson BA, Pak M, Asano K, Bjork GR, Tamame M and
602 Hinnebusch AG. The essential Gcd10p-Gcd14p nuclear complex is required for 1-
603 methyladenosine modification and maturation of initiator methionyl-tRNA. *Genes Dev.*
604 1998;12:3650-62.
- 605 32. Masuda I, Yamaki Y, Detroja R, Tagore S, Moore H, Maharjan S, Nakano Y, Christian T,
606 Matsubara R, Lowe TM, Frenkel-Morgenstern M and Hou YM. tRNA methylation resolves
607 codon usage bias at the limit of cell viability. *Cell Rep.* 2022;41:111539.
- 608 33. Doenst T, Nguyen TD and Abel ED. Cardiac metabolism in heart failure: implications
609 beyond ATP production. *Circ Res.* 2013;113:709-24.
- 610 34. Vasquez-Trincado C, Garcia-Carvajal I, Pennanen C, Parra V, Hill JA, Rothermel BA and
611 Lavandero S. Mitochondrial dynamics, mitophagy and cardiovascular disease. *J Physiol.*
612 2016;594:509-25.
- 613 35. Song M, Mihara K, Chen Y, Scorrano L and Dorn GW, 2nd. Mitochondrial fission and
614 fusion factors reciprocally orchestrate mitophagic culling in mouse hearts and cultured
615 fibroblasts. *Cell Metab.* 2015;21:273-286.
- 616 36. Ritterhoff J and Tian R. Metabolic mechanisms in physiological and pathological cardiac
617 hypertrophy: new paradigms and challenges. *Nat Rev Cardiol.* 2023;20:812-829.

- 618 37. Rosca MG, Tandler B and Hoppel CL. Mitochondria in cardiac hypertrophy and heart
619 failure. *J Mol Cell Cardiol.* 2013;55:31-41.
- 620 38. Ducker GS and Rabinowitz JD. One-Carbon Metabolism in Health and Disease. *Cell*
621 *Metab.* 2017;25:27-42.
- 622 39. Lu SC and Mato JM. S-adenosylmethionine in liver health, injury, and cancer. *Physiol*
623 *Rev.* 2012;92:1515-42.
- 624 40. Agrimi G, Di Noia MA, Marobbio CM, Fiermonte G, Lasorsa FM and Palmieri F.
625 Identification of the human mitochondrial S-adenosylmethionine transporter: bacterial
626 expression, reconstitution, functional characterization and tissue distribution. *Biochem J.*
627 2004;379:183-90.
- 628 41. Chu PY, Wu HJ, Wang SM, Chen PM, Tang FY and Chiang EI. MAT2A Localization and
629 Its Independently Prognostic Relevance in Breast Cancer Patients. *Int J Mol Sci.* 2021;22.
- 630 42. Konteatis Z, Travins J, Gross S, Marjon K, Barnett A, Mandley E, Nicolay B, Nagaraja R,
631 Chen Y, Sun Y, Liu Z, Yu J, Ye Z, Jiang F, Wei W, Fang C, Gao Y, Kalev P, Hyer ML, DeLaBarre
632 B, Jin L, Padyana AK, Dang L, Murtie J, Biller SA, Sui Z and Marks KM. Discovery of AG-270,
633 a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous MTAP
634 Deletion. *J Med Chem.* 2021;64:4430-4449.
- 635 43. Kishita Y, Pajak A, Bolar NA, Marobbio CM, Maffezzini C, Miniero DV, Monne M,
636 Kohda M, Stranneheim H, Murayama K, Naess K, Lesko N, Bruhn H, Mourier A, Wibom R,
637 Nennesmo I, Jespers A, Govaert P, Ohtake A, Van Laer L, Loeys BL, Freyer C, Palmieri F,
638 Wredenberg A, Okazaki Y and Wedell A. Intra-mitochondrial Methylation Deficiency Due to
639 Mutations in SLC25A26. *Am J Hum Genet.* 2015;97:761-8.
- 640 44. Schober FA, Tang JX, Sergeant K, Moedas MF, Zierz CM, Moore D, Smith C, Lewis D,
641 Guha N, Hopton S, Falkous G, Lam A, Pyle A, Poulton J, Gorman GS, Taylor RW, Freyer C and

- 642 Wredenberg A. Pathogenic SLC25A26 variants impair SAH transport activity causing
643 mitochondrial disease. *Hum Mol Genet.* 2022.
- 644 45. Ji Y, Wang S, Cheng Y, Fang L, Zhao J, Gao L and Xu C. Identification and
645 characterization of novel compound variants in SLC25A26 associated with combined oxidative
646 phosphorylation deficiency 28. *Gene.* 2021;804:145891.
- 647 46. Agah R, Frenkel PA, French BA, Michael LH, Overbeek PA and Schneider MD. Gene
648 recombination in postmitotic cells. Targeted expression of Cre recombinase provokes cardiac-
649 restricted, site-specific rearrangement in adult ventricular muscle in vivo. *J Clin Invest.*
650 1997;100:169-79.
- 651 47. Pan T. Modifications and functional genomics of human transfer RNA. *Cell Res.*
652 2018;28:395-404.
- 653 48. Suzuki T. The expanding world of tRNA modifications and their disease relevance. *Nat*
654 *Rev Mol Cell Biol.* 2021;22:375-392.
- 655 49. Chou HJ, Donnard E, Gustafsson HT, Garber M and Rando OJ. Transcriptome-wide
656 Analysis of Roles for tRNA Modifications in Translational Regulation. *Mol Cell.* 2017;68:978-
657 992 e4.
- 658 50. Guimaraes JC, Mittal N, Gnann A, Jedlinski D, Riba A, Buczak K, Schmidt A and
659 Zavolan M. A rare codon-based translational program of cell proliferation. *Genome Biol.*
660 2020;21:44.
- 661 51. Safra M, Sas-Chen A, Nir R, Winkler R, Nachshon A, Bar-Yaacov D, Erlacher M,
662 Rossmannith W, Stern-Ginossar N and Schwartz S. The m1A landscape on cytosolic and
663 mitochondrial mRNA at single-base resolution. *Nature.* 2017;551:251-255.
- 664 52. Ozanick SG, Bujnicki JM, Sem DS and Anderson JT. Conserved amino acids in each
665 subunit of the heterologous tRNA m1A58 Mtase from *Saccharomyces cerevisiae* contribute to

- 666 tRNA binding. *Nucleic Acids Res.* 2007;35:6808-19.
- 667 53. Wang Y, Wang J, Li X, Xiong X, Wang J, Zhou Z, Zhu X, Gu Y, Dominissini D, He L,
668 Tian Y, Yi C and Fan Z. N(1)-methyladenosine methylation in tRNA drives liver tumorigenesis
669 by regulating cholesterol metabolism. *Nat Commun.* 2021;12:6314.
- 670 54. Liu F, Clark W, Luo G, Wang X, Fu Y, Wei J, Wang X, Hao Z, Dai Q, Zheng G, Ma H,
671 Han D, Evans M, Klungland A, Pan T and He C. ALKBH1-Mediated tRNA Demethylation
672 Regulates Translation. *Cell.* 2016;167:816-828 e16.
- 673 55. Zhang L, Duan HC, Paduch M, Hu J, Zhang C, Mu Y, Lin H, He C, Kossiakoff AA, Jia G
674 and Zhang L. The Molecular Basis of Human ALKBH3 Mediated RNA N(1) -methyladenosine
675 (m(1)A) Demethylation. *Angew Chem Int Ed Engl.* 2024;63:e202313900.
- 676 56. Sun Y, Dai H, Dai X, Yin J, Cui Y, Liu X, Gonzalez G, Yuan J, Tang F, Wang N, Perlegos
677 AE, Bonini NM, Yang XW, Gu W and Wang Y. m(1)A in CAG repeat RNA binds to TDP-43 and
678 induces neurodegeneration. *Nature.* 2023;623:580-587.
- 679 57. Monne M, Marobbio CMT, Agrimi G, Palmieri L and Palmieri F. Mitochondrial transport
680 and metabolism of the major methyl donor and versatile cofactor S-adenosylmethionine, and
681 related diseases: A review(dagger). *IUBMB Life.* 2022;74:573-591.
- 682 58. Guitton R, Nido GS and Tzoulis C. No evidence of extensive non-CpG methylation in
683 mtDNA. *Nucleic Acids Res.* 2022;50:9190-9194.
- 684 59. Shirakabe A, Fritzky L, Saito T, Zhai P, Miyamoto S, Gustafsson AB, Kitsis RN and
685 Sadoshima J. Evaluating mitochondrial autophagy in the mouse heart. *J Mol Cell Cardiol.*
686 2016;92:134-9.
- 687 60. Kleele T, Rey T, Winter J, Zaganelli S, Mahecic D, Perreten Lambert H, Ruberto FP,
688 Nemir M, Wai T, Pedrazzini T and Manley S. Distinct fission signatures predict mitochondrial
689 degradation or biogenesis. *Nature.* 2021;593:435-439.

- 690 61. Broderick JB, Duffus BR, Duschene KS and Shepard EM. Radical S-adenosylmethionine
691 enzymes. *Chem Rev.* 2014;114:4229-317.
- 692 62. Wang D, Liu M, Li X, Wang X and Shen Y. Expression, purification and oligomerization
693 of the S-adenosylmethionine transporter. *Protein Expr Purif.* 2020;173:105648.
- 694 63. Kotter S and Kruger M. Protein Quality Control at the Sarcomere: Titin Protection and
695 Turnover and Implications for Disease Development. *Front Physiol.* 2022;13:914296.
- 696 64. Hanson G and Collier J. Codon optimality, bias and usage in translation and mRNA decay.
697 *Nat Rev Mol Cell Biol.* 2018;19:20-30.
- 698 65. Koutmou KS, Radhakrishnan A and Green R. Synthesis at the Speed of Codons. *Trends*
699 *Biochem Sci.* 2015;40:717-718.
- 700 66. Sabi R and Tuller T. Modelling the efficiency of codon-tRNA interactions based on codon
701 usage bias. *DNA Res.* 2014;21:511-26.
- 702 67. Li P, Wang W, Zhou R, Ding Y and Li X. The m(5) C methyltransferase NSUN2
703 promotes codon-dependent oncogenic translation by stabilising tRNA in anaplastic thyroid
704 cancer. *Clin Transl Med.* 2023;13:e1466.
- 705 68. Dou X, Boyd-Kirkup JD, McDermott J, Zhang X, Li F, Rong B, Zhang R, Miao B, Chen
706 P, Cheng H, Xue J, Bennett D, Wong J, Lan F and Han JJ. The strand-biased mitochondrial DNA
707 methylome and its regulation by DNMT3A. *Genome Res.* 2019;29:1622-1634.
- 708 69. Saini SK, Mangalharra KC, Prakasam G and Bamezai RNK. DNA Methyltransferase1
709 (DNMT1) Isoform3 methylates mitochondrial genome and modulates its biology. *Sci Rep.*
710 2017;7:1525.
- 711 70. Kim TS, Kim HD, Park YJ, Kong E, Yang HW, Jung Y, Kim Y and Kim J. JNK
712 activation induced by ribotoxic stress is initiated from 80S monosomes but not polysomes. *BMB*
713 *Rep.* 2019;52:502-507.



715 **Figure 1. Feedforward SAM transport into mitochondria by SLC25A26 during cardiac**
716 **hypertrophy**

717 **A**, Schematic illustrating the SAM biosynthesis and mitochondrial transport pathways.

718 **B** and **C**, Cell-type-specific expression of *MAT2A* (**B**) and *SLC25A26* (**C**) from a single-cell
719 sequencing database (Human Protein Atlas; <https://www.proteinatlas.org/>).

720 **D**, Western blot analysis showing the tissue specificity of *MAT2A* and *SLC25A26* in mice ($N =$
721 2). Troponin T2, cardiac type (cTnT) was used as a positive heart control. Glyceraldehyde-3-
722 phosphate dehydrogenase (GAPDH) was used as a loading controls. SKM, skeletal muscle.

723 **E**, Total and subcellular SAM contents in the heart, skeletal muscle and liver. $N = 3$. Cyto,
724 cytoplasm; Mito, mitochondria.

725 **F**, Immunoblots (left) and quantification data (right) showing the expressions of *MAT2A*,
726 *MAT2B* and *SLC25A26* in transaortic constriction (TAC)-induced cardiac hypertrophy. $N = 3$.

727 **G**, Time-course effects of TAC on the SAM content in the heart measured by enzyme-linked
728 immunosorbent assay (ELISA). $N = 4$.

729 **H**, SAM contents in neonatal rat ventricular myocytes (NRVMs) treated with SAM ($1\mu\text{M}$) or
730 phenylephrine (PE; $50\mu\text{M}$), in the presence or absence of an *MAT2A* inhibitor AG-270 ($3\mu\text{M}$). N
731 $= 3$.

732 **I**, Effect of TAC on subcellular SAM distribution in fractionated mouse hearts. $N = 3$.


733 **J**, Subcellular *SLC25A26* localization in fractionated mouse (left; $N = 3$) and human (right; $N = 2$)
734 hearts with H3, VDAC1 and GAPDH as nuclear (Nuc), Mito and Cyto controls, respectively.

735 **K**, Immunoblots (left) and quantification data (right) showing the impact of TAC on subcellular
736 *SLC25A26* localization. $N = 3$.

737 **L**, Representative immunofluorescence images (upper) and quantification data (lower) showing
738 the co-localization of the Flag-tagged SLC25A26 with mitochondria (COX1) in NRVMs treated
739 with SAM or PE, with or without AG-270. *** $P < 0.001$; $N = 12$. Scale, 5 μ m.

740 Data are mean \pm SEM. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ vs. sham or vehicle, (**F**, **I** and **K**,
741 unpaired Student's t test; **G**, **H**, **L**, one-way ANOVA with Tukey's multiple comparison test).

742



743

744 **Figure 2. SLC25A26 is required for normal heart function and its deficiency exacerbates**
 745 **TAC-induced cardiac hypertrophy**

746 **A**, Schematic illustrating the generation of *Slc25a26* cardiac-specific knockout (cKO) mouse
 747 line. WT, wildtype.

748 **B**, Validation of *Slc25a26* cKO by genotyping (left upper) and expression assessments at protein
749 (left lower) and mRNA (right) levels. $N = 5$.

750 **C**, Effects of *Slc25a26* cKO on heart and lung weights twenty weeks after Tamoxifen
751 administration. $N = 9$.

752 **D**, Representative heart morphology images (left) and low-magnification H&E-stained images
753 (right) of *Slc25a26*-flox and *Slc25a26*-cKO hearts. Scale, 0.5mm.

754 **E** through **G**, Representative Echocardiography images (**E**), quantification analyzed left
755 ventricular end diastolic/systolic internal dimensions (LVID;d/LVID;s; **F**), and quantification
756 analyzed left ventricular ejection fraction (EF) and fraction shortening (FS) (**G**) of *Slc25a26*-flox
757 and *Slc25a26*-cKO hearts twenty weeks after Tamoxifen administration. $N = 9$.

758 **H**, Representative Masson trichrome staining images (left) and quantification data (right)
759 showing myocardial fibrosis in *Slc25a26*-flox and *Slc25a26*-cKO hearts twenty weeks after
760 Tamoxifen administration. Scale, 20 μ m; $N = 3$.

761 **I**, Effects of *Slc25a26* cKO on the expression of hypertrophic biomarkers natriuretic peptide A
762 (*Nppa*), natriuretic peptide B (*Nppb*), and myosin heavy chain 7 (*Myh7*) measured by qRT-PCR.
763 $N = 9$.

764 **J**, Representative heart morphology images (left) and summarized heart weight/body weight
765 (BW) ratios (right) showing the impact of *Slc25a26* cKO on TAC-induced cardiac hypertrophy.
766 $N = 7\sim 12$ as labeled on bars.

767 **K**, Impact of *Slc25a26* cKO on the lung weight/BW ratio in sham and TAC mice. $N = 7\sim 12$.

768 **L** through **N**, Representative Echocardiography images (**L**), quantification analyzed end-diastolic
769 left ventricular posterior wall thickness (LVPW;d) and LVID;d (**M**), and quantification analyzed

770 EF and FS (**N**) showing the impact of *Slc25a26* cKO on TAC-induced cardiac morphology and
771 function. $N = 7\sim 12$ as mentioned above.

772 **O**, Representative H&E-stained images of *Slc25a26*-flox and *Slc25a26*-cKO hearts with sham or
773 TAC surgeries. Scale, 20 μ m.


774 **P**, Representative Wheat germ agglutinin (WGA) staining images (left) and quantification data
775 (right) showing the cross-sectional cardiomyocyte area of *Slc25a26*-flox and *Slc25a26*-cKO
776 hearts with sham or TAC surgeries. Scale, 20 μ m. $N = 5$.

777 **Q**, Representative Masson trichrome staining images (left) and quantification data (right)
778 showing myocardial fibrosis of *Slc25a26*-flox and *Slc25a26*-cKO hearts with sham or TAC
779 surgeries. Scale, 20 μ m; $N = 3$.

780 **R**, Effects of *Slc25a26* cKO on TAC-induced expressions of *Nppa*, *Nppb*, and *Myh7*. $N = 5$.

781 Data are mean \pm SEM. n.s., not significant, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ vs. flox; # $P <$
782 0.05, ## $P < 0.01$, ### $P < 0.001$ vs. sham, (**B**, **C**, **F**, **G**, **H** and **I**, unpaired Student's t test; **J**, **K**, **M**,
783 **N**, **P**, **Q** and **R**, two-way ANOVA with Tukey's multiple comparison test).

784



785

786

Figure 3. *Slc25a26* overexpression mitigates pathological cardiac hypertrophy

787 **A**, Injection schedule of reconstructed adeno-associated virus serotype 9 (AAV9) to overexpress
788 *Slc25a26* in the heart before TAC.

789 **B**, Validation of *Slc25a26* overexpression using qRT-PCR. $N = 5$.

790 **C**, Effects of *Slc25a26* overexpression on TAC-induced heart weight gain. $N = 6\sim 10$ as labeled
791 on bars.

792 **D** through **F**, Representative Echocardiography images (**D**), quantification analyzed LVPW;d
793 and LVID;d (**E**), and quantification analyzed EF and FS (**F**) showing the impact of pre-TAC
794 *Slc25a26* overexpression on TAC-induced cardiac morphological and functional changes. $N =$
795 $6\sim 10$ as labeled on the bars.

796 **G**, Representative WGA staining images (left) and quantification data (right) showing the impact
797 of *Slc25a26* overexpression on TAC-induced cell size enlargement. Scale, $20\mu\text{m}$. $N = 3$.

798 **H**, Representative Masson trichrome staining images (left) and quantification data (right)
799 showing the impact of *Slc25a26* overexpression on TAC-induced myocardial fibrosis. Scale,
800 $20\mu\text{m}$. $N = 4$.

801 **I**, Impact of *Slc25a26* overexpression on TAC-induced expression of cardiac hypertrophy
802 biomarkers measured by qRT-PCR. $N = 5$.

803 **J**, AAV9 injection schedules to overexpression *Slc25a26* after TAC in two strategies: Post1/Po1
804 (1w post-TAC) and Post2/Po2 (7w post-TAC).

805 **K**, Validation of *Slc25a26* overexpression in two post-TAC strategies using qRT-PCR. $N = 5$.

806 **L**, Effects of *Slc25a26* overexpression at two post-TAC schedules on TAC-induced heart weight
807 gain. $N = 5\sim 9$ as indicated by dots.

808 **M** and **N**, Representative Echocardiography images (**M**) and quantification analyzed EF and FS
809 (**N**) showing the impacts of post-TAC *Slc25a26* overexpression on TAC-induced cardiac
810 dysfunction. $N = 5\sim 9$ as indicated by dots.

811 **O**, Time-course impact of *Slc25a26* overexpression on TAC-induced EF decline in the Po2
812 strategy. $N = 5\sim 8$ as mentioned above.

813 **P**, Representative H&E, WGA and Masson staining images of sham and TAC hearts with or
814 without *Slc25a26* overexpression in Po1 and Po2 strategies. Scale, 20 μ m.


815 **Q**, Quantification data of cross-sectional cardiomyocyte area (upper) and myocardial fibrosis
816 (bottom). $N = 3$.

817 **R** and **S**, Effects of *Slc25a26* overexpression on TAC-induced expressions of *Nppa*, *Nppb* and
818 *Myh7* in Po1 (**R**) and Po2 (**S**) strategies. $N = 4$.

819 Data are mean \pm SEM. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ vs. AAV9-*vector* or sham; # $P < 0.05$,
820 ## $P < 0.01$, ### $P < 0.001$ vs. sham or TAC+AAV9-*vector*, (**B** and **K**, unpaired Student's t test; **L**,
821 **N**, **O**, **Q** and **S**, one-way ANOVA with Tukey's multiple comparison test; **E**, **F**, **G**, **H**, **I** and **R**,
822 two-way ANOVA with Tukey's multiple comparison test).

823

824



826 **Figure 4. SLC25A26 regulates translation via SAM-mediated tRNA m¹A modification**

827 **A**, Principal component analysis (PCA) of the RNA-seq data from *Slc25a26*-flox (flox) and

828 *Slc25a26*-cKO (cKO) hearts with sham or TAC surgeries.

829 **B**, Gene concept analysis showing the enriched functional items in the gene profile comparison

830 between flox and cKO hearts.

831 **C**, Heatmap showing the expressions of cytosol (left) and mitochondrial (right) tRNA

832 synthetases in flox and cKO hearts.

833 **D**, Gene set enrichment analysis (GSEA) showing the upregulation of genes related to

834 aminoacyl-tRNA biosynthesis and ribosome biogenesis after *Slc25a26* deletion.

835 **E and F**, Puromycin incorporation immunoblots (left) and quantification data (right) showing the

836 protein synthesis rate (normalized to Coomassie blue staining) in the hearts with *Slc25a26* cKO

837 (**E**) or overexpression (**F**). Slc, AAV9-*Slc25a26*; Vec, AAV9-vector. *N* = 3.

838 **G**, ELISA measurements for SAM (left), m¹A (middle) and m⁶A (right) in the cytoplasmic

839 fraction of flox and cKO hearts. *N* = 3.

840 **H**, Plot of methylated tRNAs detected by m¹A RNA immunoprecipitation sequencing (RIP-seq)

841 in flox and cKO hearts.

842 **I**, Diagram of the dual luciferase reporter gene plasmid structure (upper) and the impact of

843 *Slc25a26* knockdown on translation initiation efficiency from 5' cap or internal ribosome entry

844 site (IRES) (lower). *N* = 3.

845 **J**, m¹A modification frequency aligned to tRNA variants.

846 **K and L**, The m¹A modification level of tRNA^{Leu} (**K**) and tRNA^{Thr} (**L**) variants detected by m¹A

847 RIP-seq.

848 **M**, Flowchart of the nascent translome profiling using a mass-spectrum-based technique for the
849 puromycin-incorporated peptides enriched by immunoprecipitation.

850 **N**, Protein counts detected by immunoprecipitation-mass-spectrum using anti-Puromycin
851 antibody in PE-treated NRVMs with *Slc25a26* knockdown or overexpression.

852 **O**, Plot of puromycin-incorporated proteins from PE-treated NRVMs with *Slc25a26* knockdown
853 or overexpression.

854 **P** and **Q**, Heatmap (left) and gene ontology (GO; right) analyses showing the functional clusters
855 of altered proteins by *Slc25a26* knockdown (**P**) or overexpression (**Q**).

856 **R**, Plot of the changes of translating proteins affected by *Slc25a26* knockdown in comparison
857 with their corresponding mRNA alterations from the RNA-seq analysis.

858 Data are mean \pm SEM. n.s., not significant, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ vs. flox or siNeg,
859 (**E**, **F**, **G** and **I**, unpaired Student's t test).

860

861

868 **D**, Validation of the knockdown efficiency of siRNAs targeting tRNA methyltransferases
869 TRMT6 or TRMT61A in NRVMs using qRT-PCR. $N = 3$.

870 **E**, Puromycin incorporation immunoblots (left) and quantification data (right) showing the
871 impact of *Trmt6* or *Trmt61a* knockdown on protein synthesis rate in NRVMs. $N = 3$.

872 **F**, Puromycin incorporation immunoblot (left) and quantification data (right) showing the impact
873 of *Trmt61a* knockdown on protein synthesis rate in NRVMs with *Slc25a26* knockdown. $N = 3$.


874 **G**, Validation of the knockdown efficiency of siRNAs targeting m¹A demethylases ALKBH1 or
875 ALKBH3 in NRVMs using qRT-PCR. $N = 3$.

876 **H**, Puromycin incorporation immunoblots (left) and quantification data (right) showing the
877 impact of *Alkbh1* or *Alkbh3* knockdown on protein synthesis rate in NRVMs. $N = 3$.

878 **I** and **J**, Puromycin incorporation immunoblots (left) and quantification data (right) showing the
879 impacts of *Alkbh1* knockdown (**I**) or *Alkbh3* knockdown (**J**) on protein synthesis rate in NRVMs
880 with adenovirus-mediated *Slc25a26* overexpression. $N = 3$.

881 Data are mean \pm SEM. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, (**D**, **E**, **F**, **G**, **H**, **I** and **J**, one-way
882 ANOVA with Tukey's multiple comparison test).

883



884

885

886 **Figure 6. SLC25A26/mitoSAM maintains mitochondrial fitness for optimal energy**
887 **production**

888 **A**, SAM contents in isolated mitochondria from the hearts with *Slc25a26* cKO (left) or
889 overexpression (right) measured by ELISA. $N = 3$.

890 **B**, Impact of *Slc25a26* overexpression on the methylation of mitochondrial
891 deoxyribonucleotides, including 5-methyl-2'-deoxycytidine (5-mdC), 5-(hydroxymethyl)-2'-
892 deoxycytidine (5-hmdC) and N6-methyl-2'-deoxyadenosine (6-mdA), measured by liquid
893 chromatography-mass spectrometry (LC-MS). $N = 3$.

894 **C**, ELISA measurement for mtDNA 5-mdC from the hearts with *Slc25a26* cKO (left) or
895 *Slc25a26* overexpression (right). $N = 3$.

896 **D**, mtDNA copy number calculated by the expressions of mitochondrial *Cytb* and *Ndl* in
897 contrast to the nuclear *H19* using qRT-PCR. $N = 3$.

898 **E** and **F**, Transmission electronic microscopy showing mitochondrial morphology (left) and
899 quantified abnormal mitochondria percentage (right) in the hearts with *Slc25a26* cKO (sham; **E**)
900 or *Slc25a26* overexpression (post-TAC; **F**). $N = 3$.

901 **G**, Immunoblots (left) and quantification data (right) of proteins involved in mitochondrial
902 dynamics in flox and cKO hearts. $N = 3$.

903 **H** and **I**, Representative fluorescence images (left) and quantification (right) of MitoKeima and
904 LysoTracker showing mitophagy in NRVMs with *Slc25a26* knockdown (**H**) or *Slc25a26*
905 overexpression (**I**). Scale, 10 μ m; $N = 3$.

906 **J** and **K**, Representative JC-1 staining images (left) and quantification (right) showing
907 mitochondrial membrane potential in NRVMs with *Slc25a26* knockdown (**J**) or overexpression
908 (**K**). Scale, 20 μ m; $N = 5$.

909 **L** and **M**, Oxygen consumption rate (OCR) of NRVMs with *Slc25a26* knockdown (**L**) or
910 overexpression (**M**) measured by Seahorse. AG-270, 3 μ M. $N = 5$.

911 Data are mean \pm SEM. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ vs. flox or AAV9-*vector* or si*Neg* or
912 Ad-*vector*; # $P < 0.05$, ## $P < 0.01$, ### $P < 0.001$ vs. vehicle, (**A**, **B**, **C**, **D**, **E**, **F**, **G**, **H**, **I** and **L**,
913 unpaired Student's t test; **M**, one-way ANOVA with Tukey's multiple comparison test; **J** and **K**,
914 two-way ANOVA with Tukey's multiple comparison test).

915